The National Health Surveillance Agency (ANVISA) approved the use and marketing in Brazil of the first product derived from medical cannabis with a THC concentration above 0.2%. This is Cannabis sativaGreenCare Extract (160.32 mg/ml). This is the 16th cannabis-based product approved by ANVISA.
The authorization was published in the Official Gazette (DOU) this Monday (5/9). The herbal medicine will be offered in the form of a solution, with 20 mg/ml of cannabidiol (CBD) and about 0.2% of tetrahydrocannabinol (THC).
Until then, ANVISA only approved the marketing of products with residual THC (up to 0.2%). The new regulation authorizes an active marker, with its intended function.
According to GreenCare’s head of marketing, Andrea Chulam, the main beneficiaries will be patients with conditions that cause chronic pain, such as fibromyalgia; cancer pain; and neurocognitive disorders such as dementia and Alzheimer’s. The compound is also indicated to stimulate the appetite of people with cancer and HIV.
“These are diseases that are urgent and cannot wait. When you have the first formulation of this on the market, with access, you can treat more pathologies”, says Chulam.
GreenCare expects the product made in Colombia to arrive in Brazil within six months. ANVISA considers that the user must be indicated by the doctor who attends the patient, with an individual evaluation of each case.